WaveMan
WaveMan · Company
XENE · Xenon Pharmaceuticals Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

XENE Xenon Pharmaceuticals (XENE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001582313
Quote by TradingView
C-suite buying · 2Form 144 · 2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
174
13F, latest reported quarter
Conversions, 180 days
10
Codes C/M, not in net · $67.8K priced

What the filings say about XENE

Insiders, 180 days
+$481.3K net bought
2 buyers · 4 sellers · 40% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.1M
2 notices

Xenon Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Xenon Pharmaceuticals Inc. insiders bought a net $481.3K of stock across 104 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
MORTIMER IAN
PRESIDENT & CEO
BUY
2026-10-01 SECtraded 2026-09-30
30,000
$1.1M
-5.3%
Context
  • 25 earlier Form 4 trades (code P or S) here by this insider (25 sales), the last on Mar 13, 2026.
  • The trade is 60.1% of the 49,923 shares held after it.
  • 1 other insider bought within 30 days.
  • 174 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT & CEO MORTIMER IAN bought about $1.1M of XENE on Sep 30, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 174 funds added in the latest 13F quarter.
Kelly Thomas Patrick
Chief Financial Officer
BUY
2026-10-01 SECtraded 2026-09-30
15,000
$559.7K
-5.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 15,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 174 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Kelly Thomas Patrick bought about $559.7K of XENE on Sep 30, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 174 funds added in the latest 13F quarter.
KENNEY CHRISTOPHER JOHN
Chief Medical Officer
SELL
2026-08-31 SECtraded 2026-08-28
6,368
$383.1K
-40.0%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3 sales), the last on Mar 13, 2026.
  • The trade is 907.1% of the 702 shares held after it.
  • 1 other insider sold within 30 days.
  • 174 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer KENNEY CHRISTOPHER JOHN sold about $383.1K of XENE under a 10b5-1 plan on Aug 28, 2026; 1 other insider sold within 30 days and 174 funds added in the latest 13F quarter.
KENNEY CHRISTOPHER JOHN
Chief Medical Officer
SELL
2026-08-31 SECtraded 2026-08-28
700
$42.7K
-40.0%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3 sales), the last on Mar 13, 2026.
  • The trade is 35000.0% of the 2 shares held after it.
  • 1 other insider sold within 30 days.
  • 174 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer KENNEY CHRISTOPHER JOHN sold about $42.7K of XENE under a 10b5-1 plan on Aug 28, 2026; 1 other insider sold within 30 days and 174 funds added in the latest 13F quarter.
GANNON STEVEN
Director
SELL
2026-08-13 SECtraded 2026-08-11
10,000
$640.5K
-42.2%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jun 5, 2025.
  • The trade is 534.8% of the 1,870 shares held after it.
  • 1 other insider sold within 30 days.
  • 174 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director GANNON STEVEN sold about $640.5K of XENE on Aug 11, 2026; 1 other insider sold within 30 days and 174 funds added in the latest 13F quarter.
104 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 99 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$481.3K over 180 days
+$614.8K over 90 days
more than 85% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
174 funds bought in last quarter
more than 86% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
-4612.1% net margin
below 97% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
6.7% of the float short (float per yahoo 2026-10-26) · 1.6 days to cover · settled 2026-09-30
more than 57% of Pharma & Biotech
The situation: each line is one rule over one dataset
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Oct 1PRESIDENT & CEO MORTIMER IAN bought $1.1M (Sep 30)
Oct 1Chief Financial Officer Kelly Thomas Patrick bought $559.7K (Sep 30)

Watch XENE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-12.6%12M
-19%+12%+42%+72%2025-102025-122026-022026-042026-062026-082026-10 2026-03-09 · MORTIMER IAN sold $4.0M2026-03-09 · MORTIMER IAN sold $3.7M2026-03-09 · MORTIMER IAN sold $2.6M2026-03-09 · MORTIMER IAN sold $1.9M2026-01-02 · MORTIMER IAN sold $1.7M2026-03-09 · MORTIMER IAN sold $1.3M2026-03-09 · MORTIMER IAN sold $1.3M2026-09-30 · MORTIMER IAN bought $1.1M2026-03-09 · MORTIMER IAN sold $742.5K2026-03-10 · MORTIMER IAN sold $677.4K2025-12-05 · MORTIMER IAN sold $647.3K2026-08-11 · GANNON STEVEN sold $640.5K2026-03-09 · MORTIMER IAN sold $609.1K2026-09-30 · Kelly Thomas Patrick bought $559.7K2026-03-13 · MORTIMER IAN sold $403.6K2025-12-08 · MORTIMER IAN sold $402.1K2026-08-28 · KENNEY CHRISTOPHER JOHN sold $383.1K2026-03-10 · KENNEY CHRISTOPHER JOHN sold $166.6K2026-03-10 · DiFabio Andrea sold $156.7K2026-03-09 · MORTIMER IAN sold $150.0K2025-12-08 · MORTIMER IAN sold $93.1K2026-01-02 · MORTIMER IAN sold $92.6K2026-03-13 · KENNEY CHRISTOPHER JOHN sold $77.9K2026-03-13 · DiFabio Andrea sold $74.1K2026-06-05 · PATOU GARY sold $70.3K2026-06-05 · Cannon Gillian sold $63.2K2026-08-28 · KENNEY CHRISTOPHER JOHN sold $42.7K2025-11-28 · MORTIMER IAN sold $4.4K2026-08-28 · CHRISTOPHER KENNEY filed to sell $437.7K2026-08-13 · STEVEN GANNON filed to sell $640.6K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns XENE: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
9,647,998 sh
$582.4M
BlackRock, Inc.
7,522,482 sh
$454.1M
Avoro Capital Advisors LLC
5,777,777 sh
$348.7M
Polar Capital Holdings Plc
4,570,556 sh
$275.9M
Driehaus Capital Management LLC
4,418,557 sh
$266.7M

Congress trades in XENE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

XENE planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
CHRISTOPHER KENNEY
Filed 2026-08-28
$437.7K
STEVEN GANNON
Filed 2026-08-13
$640.6K

XENE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALPS Medical Breakthroughs ETF
$4.7M position · as of 2026-05-31
2.9%
NICHOLAS PARTNERS SMALL CAP GROWTH FUND
$3.7M position · as of 2026-06-30
1.9%
Fidelity Disruptive Medicine ETF
$786.3K position · as of 2026-05-31
1.9%
Driehaus Small Cap Growth Fund
$22.5M position · as of 2026-06-30
1.4%
Goldman Sachs Future Health Care Equity ETF
$272.4K position · as of 2026-05-31
1.4%
Baron Health Care Fund
$1.5M position · as of 2026-06-30
1.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
14 registered trials, 9 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
2
Phase 2
1 active
11
Phase 3
8 active
What changed recently
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
2026-10-16 · Recruiting → Active Not Recruiting
Phase 3
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With
2026-10-14 · Recruiting → Active Not Recruiting
Phase 3
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
2026-10-14 · Enrolling By Invitation → Active Not Recruiting
Phase 3
An Open-Label Study of Azetukalner in Major Depressive Disorder
2026-10-14 · Enrolling By Invitation → Active Not Recruiting
Phase 3
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
2026-10-14 · Completion moved 2026-08 → 2026-10
Phase 3
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
2026-10-14 · Recruiting → Active Not Recruiting
Phase 3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $481.3K bought by insiders over 180 days, 174 funds added last quarter, $1.1M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

XENE financials

Net margin
-4612.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$338.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.02x
long-term 2019-12-31 (79 months older than the period end) plus current 2020-03-31 (76 months older than the period end); equity 2026-06-30
Cash flow to debt
-12.71x
TTM operating cash flow over long-term 2019-12-31 (79 months older than the period end) plus current 2020-03-31 (76 months older than the period end)
Return on equity
-43.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-41.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-46.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$3.4B
market value at close 2026-10-27 on 2026-08-03 shares, plus long-term 2019-12-31 (79 months older than the period end) plus current 2020-03-31 (76 months older than the period end), minus cash 2026-06-30
FCF yield
-9.7%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$7.5M$0$0$9.4M
Operating income-$373.1M-$279.3M-$214.1M-$129.1M
Net income-$345.9M-$234.3M-$182.4M-$125.4M
EPS (diluted)-4.36-3.01-2.73-2.06
Operating cash flow-$279.1M-$181.4M-$151.1M-$101.0M
Cash$199.2M$142.7M$148.6M$57.2M
SEC XBRL, fiscal years, as known on 2026-10-28

XENE Stock Sonar score 5/7 axes

Find similar shapesCompare

XENE ranks highest on institutional and government (86th percentile) and insider conviction (84th), and lowest on risk and compliance (44th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
54
Inputs
  • Return on equity-43.6% · 58 pct, sector of 545
  • Return on assets-41.5% · 51 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-46.7% · 54 pct, sector of 576
Financial health
46
Inputs
  • Debt to equity0.02x · 71 pct, sector of 352
  • Cash flow to debt-12.71x · 22 pct, sector of 371
Insider conviction
84
Inputs
  • Net Form 4 buying (codes P and S), 180d$907K · 87 pct, sector of 428
  • Insider buyers, 180d2 · 81 pct, sector of 437
Institutional and government
86
Inputs
  • Funds adding, latest quarter174 · 86 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
44
Inputs
  • Short interest, % of float+6.7% · 50 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+13.1% · 38 pct, sector of 511
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

XENE filings, in plain words

Are Xenon Pharmaceuticals insiders buying or selling XENE?

In the 180 days to 2026-10-28, Xenon Pharmaceuticals insiders were net buyers, a net $481.3K: $1.7M of purchases and $1.2M of sales reported on Form 4, by 2 buyers and 4 sellers.

Are there planned insider sales of XENE?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $1.1M of stock; the latest, by CHRISTOPHER KENNEY, was filed 2026-08-28.

Read the full summary

In the 180 days to 2026-10-28, Xenon Pharmaceuticals insiders were net buyers of XENE, a net $481.3K across purchases and sales reported on Form 4 by 2 buyers and 4 sellers. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. 40% of the 5 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $1.1M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies